

**Table 3**  
**The Effect of Entry of New Drugs on Sales of Existing Drugs Within the Same Class**

Equation	1	2	3	4
Total no. of drugs in class	-0.0195 (3.10)			
Cum. no. of standard review drugs in class		-0.077 (5.78)	-0.053 (4.74)	
Cum. no. of priority review drugs in class		0.065 (3.29)		0.0026 (0.15)
Number of fixed effects:				
Drug	298	298	298	298
Age	42	42	42	42
Year	6	6	6	6
N	1862	1862	1862	1862

The FDA defines priority review drugs as “drugs that appear to represent an advance over available therapy”

The FDA defines standard review drugs as “drugs that appear to have therapeutic qualities similar to those of already marketed drugs.”

Estimates of Equation (7)

$$\log S_{it} = \pi_S N\_STANDARD_{it} + \pi_P N\_PRIORITY_{it} + \sum_j \beta_j A_{ijt} + \alpha_i + \delta_t + \varepsilon_{it}$$